Seelos Therapeutics is leading the charge against central nervous system (CNS) disorders by advancing late-stage therapeutic candidates with proven mechanisms of action for patients with suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). And Mario Nacinovich welcomes Dr. Raj Mehra, Chairman, Founder, and CEO of Seelos Therapeutics, to hear all about it.
Advancing Novel Therapeutics to Address Unmet Mental Health Needs

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Seelos Therapeutics is leading the charge against central nervous system (CNS) disorders by advancing late-stage therapeutic candidates with proven mechanisms of action for patients with suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). And Mario Nacinovich welcomes Dr. Raj Mehra, Chairman, Founder, and CEO of Seelos Therapeutics, to hear all about it.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Chemotherapy Strategies for Metastatic PDAC
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?